Transplantation versus chemotherapy in acute leukemia

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.

Bone marrow transplantation·2015

Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Bone marrow transplantation·2014

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Leukemia·2013

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Leukemia·2013

Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.

Bone marrow transplantation·2012

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Bone marrow transplantation·2011

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

iScience·2026

Self-reported side effects of tattooing: a cross-sectional study in the Swedish TABOO cohort.

BMJ public health·2026

Development of cecal volvulus after redo pancreas transplantation.

Journal of surgical case reports·2026

Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.

Iranian journal of otorhinolaryngology·2026

Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.

Journal of hepatocellular carcinoma·2026

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.

Research and practice in thrombosis and haemostasis·2026

Related Experiment Videos

Transplantation versus chemotherapy in acute leukemia

Related Concept Videos

Allogeneic hematopoietic cell transplant for AML: no impact of pre-transplant extramedullary disease on outcome.

Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms.

Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease.

Clinical outcomes of patients with desmoplastic small round cell tumor of the peritoneum undergoing autologous HCT: a CIBMTR retrospective analysis.

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS.

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Prognostic and Predictive Effect of Age in Molecularly Defined Lower-Grade Gliomas.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression.

Contemporary Management of Relapsed or Refractory Chronic Lymphocytic Leukemia.

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

Self-reported side effects of tattooing: a cross-sectional study in the Swedish TABOO cohort.

Development of cecal volvulus after redo pancreas transplantation.

Primary Diffuse Large B-Cell Lymphoma of the External Auditory Canal with Extensive Local Extension: A Case Report and Literature Review.

Early Changes in the Neutrophil-to-Lymphocyte Ratio are Associated with Conversion Outcomes in Advanced Hepatocellular Carcinoma Treated with HAIC-Based Triple Therapy.

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy.

Related Experiment Videos

Transplantation versus chemotherapy in acute leukemia

Related Concept Videos

Related Articles